Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.34 |
| ▸ | PGR | P06401 | 5/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.33 |
| ▸ | CLK3 | P49761 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23934135 | 0.88 | DAO (0.42) | DAOMAPTSNCAHRH4NR3C1 | |
| SCHEMBL23487158 | 0.84 | DAO (0.44) | DAOPDE3BPDE3AMAPTSNCA | |
| SCHEMBL24645390 | 0.82 | DAO (0.42) | DAOPDE3BPDE3AMAPTSNCA | |
| SCHEMBL14327807 | 0.80 | DAO (0.49) | DAOPDE3BPDE3AMAPTSNCA | |
| SCHEMBL27147959 | 0.78 | DAO (0.46) | DAOPDE3BPDE3AMAPTSNCA | |
| SCHEMBL23511245 | 0.78 | DAO (0.46) | DAOPDE3BPDE3AMAPTSNCA | |
| SCHEMBL27108197 | 0.78 | DAO (0.46) | DAOPDE3BPDE3AMAPTSNCA | |
| Hydrochloric Acid SCHEMBL30766026 | 0.76 | DAO (0.45) | DAOPDE3BPDE3AMAPTSNCA | |
| Hydrochloric Acid SCHEMBL27144400 | 0.76 | DAO (0.45) | DAOPDE3BPDE3AMAPTSNCA | |
| Hydrochloric Acid SCHEMBL27144401 | 0.76 | DAO (0.45) | DAOPDE3BPDE3AMAPTSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF KANSAS | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | DAO 2981/4885PDE3B 2904/4885PDE3A 2735/4885 |
| US-20210323941-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, CHRM2 | DAO 1368/4885PDE3B 338/4885PDE3A 215/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | DAO 2981/4885PDE3B 2904/4885PDE3A 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.